StockNews.AI
ENVB
StockNews.AI
27 days

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

1. Enveric received a second Notice of Allowance from the USPTO for EVM401 compounds. 2. This expands its intellectual property in treating mental health disorders.

2m saved
Insight
Article

FAQ

Why Bullish?

The additional patent could enhance ENVB's market position and investor confidence, similar to past approvals seen in biotech firms positively affecting stock prices.

How important is it?

Strengthening its patent portfolio is crucial for ENVB's growth trajectory and justifies high investor interest.

Why Long Term?

This patent could provide strategic advantages and sustained market interest, akin to other biotech IP developments that yielded long-term benefits.

Related Companies

VRTXNTRBAXSM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent applic.

Related News